Comparison of Choroidal Thickness Changes following Intravitreal Dexamethasone, Ranibizumab, and Triamcinolone in Eyes with Retinal Vein Occlusion

Yumuşak, Erhan; Örnek, Kemal; Dikel, Nevin Hande

doi:10.5301/ejo.5000734

Cited by 18 publications

(21 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These data confirm the importance of a deep analysis of visual function in patients affected by macular edema [ 17 , 20 ]. The presence of intraretinal cysts, intraretinal layers disruption, hemorrhages, and foveal depression loss could modify macular sensitivity and the possibility of fixation, affecting in this way the quality of central visual function.…”

Section: Discussionsupporting

confidence: 79%

Evaluation of the Effectiveness of Treatment with Dexamethasone Intravitreal Implant in Cystoid Macular Edema Secondary to Retinal Vein Occlusion

Donati

Gandolfi

Caprani

et al. 2018

BioMed Research International

View full text Add to dashboard Cite

Purpose To evaluate retinal functional improvement by means of visual acuity and retinal sensibility examination after intravitreal dexamethasone implant in patients affected by cystoid macular edema secondary to retinal vein occlusion. Methods Twenty-six consecutive patients affected by retinal vein occlusion complicated by cystoid macular edema were enrolled in this prospective interventional study. All patients underwent a baseline complete ophthalmological evaluation as well as retinal angiography, OCT examination, and microperimetry evaluation. Each patient was treated with intravitreal injection of a long-term steroid implant (Ozurdex, Allergan). Follow-up evaluations were performed at months 1, 3, and 6 and completed by OCT and MP1 examination. Clinical data underwent statistical analysis. Results Baseline functional evaluation showed mean visual acuity of 0,63±0,42 LogMAR and retinal sensitivity of 7,93±4,73 dB (mean±standard deviation); after treatment, at day 30 we found, respectively, 0,43±0,38 LogMAR (p<0.05, compared to baseline) and 10,15±4,410 dB (p<0.05); at day 90, we found 0,44±0,32 (p<0.05) and 9.61±4,29 dB (p<0.05); at day 180, we found 0,41±0,31 (p<0.05) and 9,95±3,79 dB (p<0.05). Fixation pattern improved significantly (p<0.05), showing a stable fixation in 30% of patients at baseline, increasing to 77% of patients at day 180. Baseline morphological evaluation showed a central retinal thickness (CRT) of 398,21±181,65 μm after treatment; we found a CRT of 222,64±95,21 μm at day 30 (p<0.05, compared to baseline), 307,50±120,25 μm (p<0.05) at day 90, and 294,93±135,86 μm (p<0.05) at day 180. About 15,3% patients showed already at month 3 a recurrence of macular edema. They underwent a retreatment before month 6 as for treatment guidelines. Conclusion Our detailed analysis showed the significative increase in retinal function in the early phases of the follow-up. Retinal sensibility showed a stronger correlation than VA in macular edema reabsorption, better underlying the progressive functional recovery and increase in quality of vision and life for the patients. This trial is registered with ClinicalTrials.gov NCT03559491.

show abstract

Section: Discussionsupporting

confidence: 79%

Evaluation of the Effectiveness of Treatment with Dexamethasone Intravitreal Implant in Cystoid Macular Edema Secondary to Retinal Vein Occlusion

Donati

Gandolfi

Caprani

et al. 2018

BioMed Research International

View full text Add to dashboard Cite

show abstract

“… 17 , 18 Therapeutical approaches such as intravitreal injections or surgical manipulation have also been shown to affect the choroid. 19 …”

Section: Discussionmentioning

confidence: 99%

Variability of choroidal and retinal thicknesses in healthy eyes using swept-source optical coherence tomography – implications for designing clinical trials

Caramoy

Heindl

2017

OPTH

View full text Add to dashboard Cite

AimThe aim was to study the variability of choroidal scleral interface (CSI) thickness in healthy subjects and its relevance for designing future studies.MethodsA total of 123 volunteers were imaged using swept-source optical coherence tomography. Early treatment diabetic retinopathy grid was used.ResultsMean central retinal thickness was 285.85±14.53 µm and 287.18±12.93 µm, and mean central CSI thickness was 273.94±77.77 µm and 271.19±78.85 µm for the right and left eyes, respectively. Mean retinal and CSI thicknesses correlated negatively with age (p=0.023, r=−0.208 and p<0.0001, r=−0.426, respectively) and axial length (p=0.016, r=−0.220 and p<0.0001, r=−0.504, respectively). To detect a CSI change of at least 112 µm, a sample size of 11 or 36 per group is needed for a single- or double-arm study, respectively (α=0.05, power =0.90, no loss to follow-up, assuming standard deviation in future studies as 100 µm).ConclusionFuture clinical studies using CSI as end point are possible with regard to sample size needed.

show abstract

“…Besides, SFCT change after anti-VEGF therapy was also contradictory [14,15] . Most of the studies reported that the SFCT was decreased significantly after anti-VEGF treatment [12,16] , while a few studies reported that SFCT didn't decrease after anti-VEGF treatment [9] . Thus, these contradictory results warrant further investigation.…”

Section: Introductionmentioning

confidence: 99%

Comparison of subfoveal choroidal thickness in eyes with CRVO and BRVO

Tang

Zhong

et al. 2019

Preprint

View full text Add to dashboard Cite

Backgroud: To evaluate the subfoveal choroidal thickness (SFCT) in eyes with macular edema (ME) secondary to retinal vein occlusion（RVO），and to investigate the short term response after a single intravitreal ranibizumab (IVR) injection. What is more, to compare SFCT and SFCT change between central RVO (CRVO) and branch RVO (BRVO). Methods: In the retrospective study, we had collected thirty-six treatment-naïve patients with unilateral ME secondary to RVO (including nineteen CRVO and seventeen BRVO). All patients had received IVR injection after newly diagnosed. The SFCT was measured at the onset and after two weeks of IVR injection. Paired t test was performed to compare the SFCT of RVO eyes and fellow eyes, as well as the SFCT of pre-injection and post-injection. In further, independent t test was used to compare SFCT and SFCT change between CRVO eyes and BRVO eyes. Results: The mean SFCT at the onset was 326.03±30.86 μm in CRVO eyes, which was significantly thicker than that in contralateral fellow eyes (p<0.01, paired t test), and reduced to 294.15±30.83 μm rapidly after two weeks of IVR injection (p<0.01, paired t test). Similarly, the SFCT in BRVO eyes was significantly thicker than that in contralateral eyes at the onset, and decreased significantly after IVR injection. However, our findings showed that there was no statistically significant difference in SFCT and SFCT reduction after IVR injection between CRVO eyes and BRVO eyes. Conclusions: The SFCT in eyes with ME secondary to CRVO and BRVO was significantly thicker than that in fellow eyes, and decreased significantly within a short time in response to a single IVR injection. In further, the study showed that SFCT and SFCT change had no correlation with RVO subtypes.

show abstract

Comparison of Choroidal Thickness Changes following Intravitreal Dexamethasone, Ranibizumab, and Triamcinolone in Eyes with Retinal Vein Occlusion

Abstract: Choroidal thickness was decreased in all 3 groups. The DEX and TA groups showed a significant reduction at some areas. Ranibizumab had the smallest effect on choroidal thickness after 3 months among all groups.

Cited by 18 publications

References 34 publications

Evaluation of the Effectiveness of Treatment with Dexamethasone Intravitreal Implant in Cystoid Macular Edema Secondary to Retinal Vein Occlusion

Evaluation of the Effectiveness of Treatment with Dexamethasone Intravitreal Implant in Cystoid Macular Edema Secondary to Retinal Vein Occlusion

Variability of choroidal and retinal thicknesses in healthy eyes using swept-source optical coherence tomography – implications for designing clinical trials

Comparison of subfoveal choroidal thickness in eyes with CRVO and BRVO

Contact Info

Product

Resources

About

Comparison of Choroidal Thickness Changes following Intravitreal Dexamethasone, Ranibizumab, and Triamcinolone in Eyes with Retinal Vein Occlusion

Abstract: Choroidal thickness was decreased in all 3 groups. The DEX and TA groups showed a significant reduction at some areas. Ranibizumab had the smallest effect on choroidal thickness after 3 months among all groups.

Cited by 18 publications

References 34 publications

Evaluation of the Effectiveness of Treatment with Dexamethasone Intravitreal Implant in Cystoid Macular Edema Secondary to Retinal Vein Occlusion

Evaluation of the Effectiveness of Treatment with Dexamethasone Intravitreal Implant in Cystoid Macular Edema Secondary to Retinal Vein Occlusion

Variability of choroidal and retinal thicknesses in healthy eyes using swept-source optical coherence tomography &ndash; implications for designing clinical trials

Comparison of subfoveal choroidal thickness in eyes with CRVO and BRVO

Contact Info

Product

Resources

About

Variability of choroidal and retinal thicknesses in healthy eyes using swept-source optical coherence tomography – implications for designing clinical trials